FGFR aberrations increase the risk of brain metastases and predict poor prognosis in metastatic breast cancer patients.

ABSTRACT:

Background

The survival status of patients with breast cancer and brain metastasis (BCBM) receiving current treatments is poor.

Method

We designed a real-world study to investigate using patients' clinical and genetic aberrations to forecast the prognoses of BCBM patients. We recruited 146 BCBM patients and analyzed their clinical features to evaluate the overall survival (OS). For genetic testing, 30 BCBM and 165 non-brain-metastatic (BM) metastatic breast cancer (MBC) patients from Hunan Cancer Hospital, and 86 BCBM and 1416 non-BM MBC patients from the Geneplus database who received circulating tumor DNA testing, were compared and analyzed.

Results

Ki67 >14% and >3 metastatic brain tumors were significant risk factors associated with poor OS, while chemotherapy and

SUBMITTER: Xie N 

PROVIDER: S-EPMC7243401 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature